Physician profile
Stuart L Posner
NPI 1679536676
$1,124.53
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.47 · 2022: $634 · 2023: $423 · 2024: $23.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $247.53 | 2022-2023 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $170.38 | 2021-2023 | |
| Ucb, INC. | $134.16 | 2022-2023 | Cimzia |
| Lilly USA, LLC | $120.53 | 2022-2023 | Taltz |
| Glaxosmithkline, LLC. | $106.11 | 2021-2023 | Benlysta |
| Mylan Institutional INC. | $50.48 | 2023 | Hulio |
| Fresenius Kabi USA, LLC | $47.70 | 2023 | |
| Pfizer INC. | $46.26 | 2023 | |
| Mallinckrodt Hospital Products INC. | $39.35 | 2022 | |
| Janssen Biotech, INC. | $36.97 | 2022 | |
| Genentech USA, INC. | $26.08 | 2022 | |
| Insmed, INC. | $23.17 | 2024 | Arikayce |
| Sobi, INC | $22.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.31 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.51 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $15.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Posner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.